A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Amgen Inc stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 18,373 shares of AMGN stock, worth $5.8 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
18,373
Previous 18,662 1.55%
Holding current value
$5.8 Million
Previous $5.34 Billion 99.89%
% of portfolio
0.03%
Previous 0.04%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$262.75 - $319.31 $75,934 - $92,280
-289 Reduced 1.55%
18,373 $5.74 Million
Q1 2024

May 15, 2024

BUY
$268.87 - $324.56 $5.02 Million - $6.06 Million
18,662 New
18,662 $5.34 Billion
Q4 2023

Aug 14, 2024

SELL
$255.7 - $288.46 $1.14 Million - $1.28 Million
-4,443 Reduced 22.93%
14,935 $4.3 Billion
Q3 2023

Aug 14, 2024

SELL
$218.65 - $271.46 $509,673 - $632,773
-2,331 Reduced 10.74%
19,378 $5.21 Billion
Q2 2023

Aug 14, 2024

BUY
$214.27 - $253.37 $1.3 Million - $1.54 Million
6,089 Added 38.98%
21,709 $4.82 Billion
Q1 2023

Aug 14, 2024

BUY
$225.79 - $275.2 $1.87 Million - $2.28 Million
8,279 Added 112.78%
15,620 $3.78 Billion
Q4 2022

Aug 14, 2024

SELL
$229.03 - $291.01 $2.14 Million - $2.72 Million
-9,346 Reduced 56.01%
7,341 $1.93 Billion
Q3 2022

Aug 14, 2024

BUY
$224.46 - $253.15 $282,595 - $318,715
1,259 Added 8.16%
16,687 $3.76 Billion
Q2 2022

Aug 14, 2024

BUY
$230.71 - $256.74 $379,517 - $422,337
1,645 Added 11.93%
15,428 $3.75 Billion
Q1 2022

Aug 14, 2024

SELL
$219.27 - $242.57 $1.01 Million - $1.11 Million
-4,590 Reduced 24.98%
13,783 $3.33 Billion
Q4 2021

Aug 30, 2024

BUY
$198.88 - $227.6 $608,572 - $696,456
3,060 Added 12.62%
27,312 $6.14 Billion
Q3 2021

Aug 30, 2024

SELL
$212.27 - $248.7 $734,454 - $860,502
-3,460 Reduced 12.49%
24,252 $5.16 Billion
Q2 2021

Aug 30, 2024

BUY
$233.58 - $259.14 $2.18 Million - $2.42 Million
9,339 Added 50.83%
27,712 $6.75 Billion
Q1 2021

Aug 30, 2024

BUY
$221.91 - $258.6 $2.46 Million - $2.87 Million
11,092 Added 72.8%
26,329 $6.55 Billion
Q4 2020

Aug 30, 2024

BUY
$216.38 - $257.67 $2.28 Million - $2.71 Million
10,535 Added 224.05%
15,237 $3.5 Billion
Q3 2020

Aug 30, 2024

BUY
$234.65 - $260.95 $39,655 - $44,100
169 Added 3.73%
4,702 $1.2 Billion
Q2 2020

Aug 30, 2024

SELL
$197.81 - $242.74 $557,626 - $684,284
-2,819 Reduced 38.34%
4,533 $1.07 Billion
Q1 2020

Aug 30, 2024

SELL
$182.24 - $241.7 $3.27 Million - $4.34 Million
-17,947 Reduced 70.94%
7,352 $1.49 Billion
Q4 2019

Aug 30, 2024

BUY
$189.21 - $243.2 $843,687 - $1.08 Million
4,459 Added 21.4%
25,299 $6.1 Billion
Q3 2019

Aug 30, 2024

BUY
$174.11 - $208.62 $59,893 - $71,765
344 Added 1.68%
20,840 $4.03 Billion
Q2 2019

Aug 30, 2024

BUY
$166.7 - $195.41 $173,368 - $203,226
1,040 Added 5.35%
20,496 $3.78 Billion
Q1 2019

Aug 30, 2024

SELL
$180.87 - $203.88 $76,146 - $85,833
-421 Reduced 2.12%
19,456 $3.7 Billion
Q4 2018

Aug 30, 2024

BUY
$178.4 - $208.25 $268,313 - $313,208
1,504 Added 8.19%
19,877 $3.87 Billion
Q3 2018

Aug 30, 2024

BUY
$185.29 - $208.89 $10,932 - $12,324
59 Added 0.3%
19,897 $4.12 Billion
Q2 2018

Aug 30, 2024

SELL
$166.05 - $186.51 $681,635 - $765,623
-4,105 Reduced 17.14%
19,838 $3.66 Billion
Q1 2018

Aug 30, 2024

SELL
$169.43 - $198.0 $361,733 - $422,730
-2,135 Reduced 8.19%
23,943 $4.08 Billion
Q4 2017

Aug 30, 2024

SELL
$168.79 - $188.59 $1.18 Million - $1.31 Million
-6,964 Reduced 21.08%
26,078 $4.53 Billion
Q3 2017

Aug 30, 2024

SELL
$167.29 - $191.0 $33,458 - $38,200
-200 Reduced 0.6%
33,042 $6.16 Billion
Q2 2017

Aug 30, 2024

BUY
N/A
7,009 Added 26.72%
33,242 $5.73 Billion
Q1 2017

Aug 30, 2024

BUY
N/A
7,860
26,233 $4.3 Billion

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $169B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.